Elanco Animal Health (NYSE:ELAN) Reaches New 1-Year High - Here's Why

Key Points

• Elanco Animal Health's stock reached a new 52-week high of $19.09 during trading, closing at $19.00 with over 2.5 million shares traded.
• Analysts are optimistic about the stock, with upgrades leading to a consensus rating of "Moderate Buy" and a price target of $17.33.
• The company reported earnings per share (EPS) of $0.26 for the last quarter, exceeding expectations and showing a 4.8% year-over-year revenue increase to $1.24 billion.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) hit a new 52-week high on Thursday . The company traded as high as $19.09 and last traded at $19.00, with a volume of 2542096 shares trading hands. The stock had previously closed at $18.43.

Wall Street Analysts Forecast Growth

ELAN has been the subject of a number of research reports. Piper Sandler boosted their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, August 11th. Zacks Research lowered Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective on the stock in a report on Thursday, July 17th. UBS Group raised their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, August 8th. Finally, Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $17.33.

Elanco Animal Health Trading Down 0.6%

The firm has a market capitalization of $9.48 billion, a PE ratio of 21.33, a P/E/G ratio of 3.56 and a beta of 1.62. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The firm has a fifty day moving average of $16.77 and a 200 day moving average of $13.48.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company's revenue was up 4.8% on a year-over-year basis. During the same period last year, the business posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently modified their holdings of the stock. Nuveen LLC acquired a new position in shares of Elanco Animal Health in the 1st quarter worth approximately $115,212,000. Dimensional Fund Advisors LP grew its position in shares of Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after acquiring an additional 2,563,740 shares in the last quarter. Jennison Associates LLC grew its position in shares of Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company's stock worth $46,192,000 after acquiring an additional 2,468,122 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. acquired a new position in shares of Elanco Animal Health in the 1st quarter worth approximately $23,744,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.